R-BAC方案在BTK抑制剂治疗后复发难治套细胞淋巴瘤中的疗效
本回顾性队列研究纳入BTK抑制剂治疗后进展的套细胞淋巴瘤患者,接受R-BAC方案(利妥昔单抗、苯达莫司汀、阿糖胞苷)治疗。总缓解率83%(完全缓解60%),31%患者桥接至异基因造血干细胞移植。
要点
- R-BAC在BTK抑制剂治疗后进展的套细胞淋巴瘤中总缓解率达83%。
- 31%患者可桥接至异基因移植,移植巩固后仅1例复发。
核心结论
- R-BAC在BTK抑制剂治疗后套细胞淋巴瘤中显示高缓解率,对适合移植患者是有效的异基因移植桥接方案。
研究设计与样本
- 回顾性队列研究,纳入BTK抑制剂治疗后进展的套细胞淋巴瘤患者,接受R-BAC方案治疗。
主要发现
- 总缓解率83%,完全缓解率60%。
- 31%患者桥接至异基因造血干细胞移植。
- 异基因移植巩固后仅1例患者复发。
临床怎么用
- 对BTK抑制剂治疗后进展且适合移植的套细胞淋巴瘤患者,可考虑R-BAC作为桥接异基因移植的方案。
局限性
- 回顾性队列研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with mantle cell lymphoma progressing on Bruton's tyrosine kinase inhibitor (BTKi) have very poor prognosis and there is currently no standard of care. In this retrospective cohort study, patients progressing on BTKi received R-BAC (rituximab, bendamustine, cytarabine). Overall response rate was 83% (complete response 60%) and 31% were bridged to allogeneic stem cell transplant (alloSCT). Median progression-free survival was 10.1 months (95% confidence interval (CI) 6·9-13·3) and median overall survival was 12·5 months (95% CI 11·0-14·0). In those consolidated with alloSCT only one patient relapsed. R-BAC demonstrates a high response rate in the post-BTKi setting and in transplant eligible patients is an effective bridge to alloSCT.
引用
- McCulloch R, Visco C, Eyre TA, et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol. 2020. PMID: 32011729. doi:10.1111/bjh.16416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。